Medtech company Nukute has raised funding of €4.1m through its Series A funding round.
A further €4.9m has been raised through public funding.
The single largest investment came from the Pharmacy Pension Fund (Finland), with funding of €3m.
A statement from the company said: “The company is moving forward with clinical trials and the obtaining of the CE marking for the added functionality to the Nukute Collare system. This addition will facilitate the remote monitoring of acute respiratory distress syndrome (ARDS) in COVID-19 patients. The funding will also be used for the entry to the European market and next generation product development.”
Nukute, founded in 2015 by CEO Toni Leinonen and Tuukka Visuri, provides high-tech medical solutions for remote monitoring and diagnosing of respiratory illnesses and conditions via tracheal listening of the human respiratory system, combined with highly evolved cloud-computing and AI.